eli lilly trial retatrutide Retatrutide, the next generation of GLP-1 drug from Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In Eli Lilly Advances Leukemia Drug

Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry

Your prescriber can help decide whether a pill or injection, or a combination over time, fits best with your long-term weight-loss plan

Safety and efficacy of dipeptidyl peptidase4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis

Evaluating the use of glucagonlike peptide 1 for the treatment of cognitive dysfunction in individuals with mood disorders

Originally approved for type 2 diabetes and later for obesity treatment, GLP-1 and other incretin-based therapies have rapidly gained traction in both clinical and consumer spaces